Denali Therapeutics Inc (DNLI NASDAQ) stock market data APIs
$14.2148
0.1(0.7%)
as of July 7, 2025
Try our APIs with
free plan!
Denali Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Prev. Close
14.2148
Open
14.3155
High
14.7308
Low
13.9818
52 wk Range
10.57-33.33
Market Cap
2 070 M
Shares Outstanding
145 M
EPS
-0.78
Beta
1.328
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Denali Therapeutics Inc data using free add-ons & libraries
Get Denali Therapeutics Inc Fundamental Data
Denali Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -513 951 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.7043
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Denali Therapeutics Inc News
New
William Blair reiterates Outperform rating on Denali stock after BLA acceptance
Investing.com - William Blair has reiterated its Outperform rating on Denali Therapeutics Inc. (NASDAQ:DNLI) following the Biologics License Application (BLA) acceptance and priority review for the ...
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
Denali Therapeutics Inc. FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross...
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
A month has gone by since the last earnings report for Denali Therapeutics Inc. (DNLI). Shares have added about 0.7% in that time frame, underperforming the S&P 500. Will the recent positive trend co...
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recur...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
